BPC-157 TB-500: questions, answered from the record.

Definitions and the blend

What is the Wolverine peptide blend?

Wolverine is a research-community name for a two-peptide pairing of BPC-157 and TB-500, marketed and discussed as a tissue-repair "stack." It is not a single chemical entity, has no single molecular weight or CAS number, and is not an approved product anywhere.

What is BPC-157 and TB-500?

BPC-157 is a synthetic 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a human gastric-juice protein; TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region (residues 17-23) of Thymosin Beta-4. The Wolverine blend pairs the two as a research-community tissue-repair stack; it is not a single chemical entity or an approved product.

What is the BPC-157 and TB-500 blend used for in research?

Its two components occupy complementary nodes of a tissue-repair network in preclinical work: BPC-157 for cytoprotection, angiogenesis, and tendon repair in rodent models ^[1], and TB-500 / Thymosin Beta-4 for actin-regulated cell migration and re-epithelialization in animal and biochemical models ^[4]. The assembled blend itself has not been tested in a controlled study.

What is the difference between BPC-157 and TB-500?

BPC-157 is a 15-amino-acid pentadecapeptide derived from a gastric-juice protein, acting through VEGFR2-driven angiogenesis and cytoprotection ^[2]. TB-500 is a 7-amino-acid acetylated fragment (Ac-LKKTETQ) of Thymosin Beta-4, acting through G-actin sequestration that regulates cell migration ^[3]. They differ in size, origin, and primary mechanism, which is why they are paired as complementary repair signals.

Mechanism

Why are BPC-157 and TB-500 combined (the Wolverine stack)?

The rationale is complementary mechanisms: BPC-157 supplies a local cytoprotective and pro-angiogenic signal via VEGFR2-Akt-eNOS ^[2], while TB-500 / Thymosin Beta-4 supplies an intracellular actin-sequestration signal that regulates cell migration ^[3]. The two are described as acting through complementary but largely non-overlapping pathways — the basis of the synergy claim, which remains a theoretical extrapolation.

How does TB-500 work (actin / Thymosin Beta-4)?

TB-500's LKKTETQ motif binds monomeric G-actin 1:1 and sequesters it, regulating the cytoskeletal dynamics that drive cell migration and re-epithelialization. X-ray crystallography of a gelsolin-domain-Thymosin Beta-4 hybrid bound to actin established this 1:1 dual-end-capping mechanism ^[3]. Note: most efficacy data attributed to TB-500 were generated with full-length Thymosin Beta-4, not the 7-mer ^[4].

How does BPC-157 work compared to TB-500?

BPC-157 works through a cytoprotective and angiogenic route — up-regulating VEGFR2 with downstream Akt-eNOS signaling and modulating the nitric-oxide system ^[2] — while TB-500 works through actin sequestration that regulates cell migration ^[3]. They are described as complementary but largely non-overlapping mechanisms, which is the rationale for pairing them in the blend.

Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?

Both promote angiogenesis by distinct routes in preclinical models. BPC-157 up-regulates VEGFR2 and promotes its internalization with downstream VEGFR2-Akt-eNOS signaling, increasing vessel density and blood-flow recovery in ischemic muscle ^[2]. Thymosin Beta-4, TB-500's parent, promotes endothelial migration and angiogenesis in animal models ^[4].

Evidence and efficacy

Is there any study showing BPC-157 and TB-500 work better together (synergy)?

No. No peer-reviewed study has defined a synergy ratio, dose, or endpoint for the two peptides given together. A 2025 systematic review of BPC-157 in orthopaedic sports medicine — 36 studies, only one human, no clinical safety data — makes no mention of TB-500 or any combination ^[9]. Synergy is extrapolated from each peptide's separately characterized mechanism, not demonstrated in a controlled combination study.

Are there human clinical trials on the BPC-157 + TB-500 combination?

There are no controlled clinical trials of the combination for any indication. Human data exist only for the individual constituents and are themselves thin: BPC-157 has three small pilot studies, and "TB-500" human data are for full-length Thymosin Beta-4 — Phase 1 IV studies in 40 ^[6] and 84 ^[7] volunteers — not the heptapeptide. The blend's human efficacy and combination safety are unproven.

Does the BPC-157 TB-500 blend help tendon and ligament injuries?

The tendon evidence is preclinical and single-compound. BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, and microscopic measures, and in vitro reversed growth inhibition of tendocytes into stimulation ^[1]. No controlled study has tested the combined blend in tendon or ligament injury.

Does BPC-157 and TB-500 help muscle tears and recovery?

Muscle-repair signals are preclinical and single-compound. A consolidated review of Thymosin Beta-4 (TB-500's parent) describes actin-driven cell mobilization, migration, and stem-cell activity relevant to tissue repair ^[4], and BPC-157 contributes a cytoprotective and angiogenic signal ^[2]. But recent reviews emphasize the evidence is low-tier, and no controlled combination muscle-recovery trial exists ^[10].

Dosing and handling

What is the half-life of BPC-157 and TB-500?

No validated human pharmacokinetic half-life exists for either constituent at research-use doses, and none for the blend. BPC-157's elimination half-life was reported as under 30 minutes in a rat/dog PK study, with modest intramuscular bioavailability and rapid breakdown into small peptide fragments ^[5]. Human IV full-length Thymosin Beta-4 showed dose-proportional PK ^[6], but no specific half-life is established for the TB-500 heptapeptide.

How do you reconstitute a BPC-157 / TB-500 blend (10mg)?

Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated. Commercial vials are commonly labeled with a combined per-vial mass (e.g. 10 mg plus 10 mg), but product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed. No human-use reconstitution instructions apply to a research chemical.

How often should you inject BPC-157 and TB-500?

There is no validated human injection frequency for the blend. The underlying animal studies use widely differing schedules — e.g. Thymosin Beta-4 at 150 µg twice weekly for six months in one mouse study ^[4] — and community frequency protocols have no controlled-trial basis. Framing should describe doses as studied in a species, not recommend human schedules.

How much BPC-157 and TB-500 should be used per week?

No validated weekly amount exists for the blend. Commercial labeling commonly pairs fixed combined masses per vial (e.g. ~10 mg plus ~10 mg), but no peer-reviewed combination dose-finding study supports any weekly figure. Component animal doses are expressed per body weight by species and route ^[1][4] and do not translate to human weekly schedules.

Can BPC-157 and TB-500 be taken orally instead of injected?

BPC-157 is studied as a "stable gastric" peptide and oral blend products are marketed, but no validated oral pharmacokinetics exist for the blend. A formal PK study reported modest intramuscular bioavailability for BPC-157 in rats and dogs ^[5]; comparable validated oral bioavailability data for the blend are not established. Oral framing should not be presented as a proven research route.

Can you mix BPC-157 with TB-500 in the same syringe?

A common research-community practice is to reconstitute the two peptides separately or in a shared vial, but product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed, and no controlled study validates a combined preparation. This is a handling question about a research chemical, not human-use guidance.

How do you cycle BPC-157 and TB-500?

No validated human cycling protocol exists. Community loading-then-maintenance blend protocols have no controlled-trial basis, and a rat embolic-stroke study found Thymosin Beta-4 dosing non-monotonic — 18 mg/kg gave no benefit ^[4] — undermining "more is better" loading rationales. Component animal studies use widely differing schedules by species and route ^[1][4].

Safety

What are the side effects of BPC-157 and TB-500?

The assembled blend has no controlled human safety data. Component human data are limited: Phase 1 studies of full-length Thymosin Beta-4 were well tolerated ^[6][7], but a 2026 review cautions that rigorous human safety data for unapproved musculoskeletal peptides are scarce, with potential for serious harm ^[10]. The principal theoretical concern is the pro-angiogenic, pro-migratory tumor signal associated with Thymosin Beta-4.

Does TB-500 cause cancer or promote tumor growth?

Thymosin Beta-4 has been implicated in tumor metastasis and angiogenesis — the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression, a concern that compounds when two pro-repair peptides are combined. This is a recognized safety signal, not a demonstrated effect of the blend; no carcinogenicity data exist for the combination ^[4][10].

Legal status and access

Are BPC-157 and TB-500 FDA approved or banned by WADA?

Neither is approved by the FDA for human use, and the blend has no approved therapeutic indication. In 2023 the FDA placed BPC-157 in a category of bulk drug substances not eligible for 503A pharmacy compounding pending further evaluation, and the LKKTETQ fragment known as TB-500 was placed in the same Category 2 ^[12]. Both constituents are prohibited by WADA (BPC-157 under S0; TB-500 / Thymosin Beta-4 under prohibited peptide and growth-factor categories).

Is Wolverine legal?

The Wolverine blend is not an FDA-approved drug, and neither component is approved for human use. Both BPC-157 and TB-500 currently sit in FDA's 503A Category 2, effective with the September 29, 2023 list update ^[12], so compounding-pharmacy access is presently restricted. That status is under active FDA review, with a PCAC meeting scheduled for July 23-24, 2026 ^[13]. This is general information, not legal advice.

Can you get BPC-157 from a compounding pharmacy?

Not under routine 503A compounding as the rules currently stand. The FDA placed BPC-157 in 503A Category 2 effective September 29, 2023, identifying it as a possible significant-safety-risk bulk substance not covered by enforcement discretion ^[12]. Lawful compounded access generally requires a licensed-prescriber evaluation, a valid prescription, and a 503A or 503B facility — and the ingredient must be eligible, which BPC-157 is not while this status stands ^[14].

What is the FDA 503A status of Wolverine?

Both of the blend's components are in 503A Category 2. The FDA placed BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" in Category 2 effective with the September 29, 2023 update, citing significant-safety-risk concerns ^[12]. Both appear on the July 23-24, 2026 PCAC agenda as substances being considered for the 503A bulks list — a scheduled evaluation, not a decision ^[13].